Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative radiotherapy with or without short-term androgen suppression in high-risk prostate cancer
2006-002772-17Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in prostate cancer (PCa) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Biochemical progression-free survival. Started Mar 2009; status: terminated.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-002772-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002772-17.